Literature DB >> 8046247

A cultured malignant B-1 line serves as a model for Richter's syndrome.

B Peng1, D H Sherr, F Mahboudi, J Hardin, Y H Wu, L Sharer, E S Raveché.   

Abstract

Human chronic lymphocytic leukemia (CLL) is a malignancy of B-1 cells characterized by the accumulation of mature appearing, long lived, slow growing B-1 cells in peripheral blood. CLL occasionally evolves into an aggressive large cell lymphoma termed Richter's syndrome. NZB mice can be used to model the early stage of CLL because aged NZB mice can spontaneously develop slow growing malignant B-1 cell clones. The malignant NZB B-1 clones fail to grow in culture and are typically carried in vivo as passaged lines. During serial passage, an aggressive lymphoma developed as a result of a continued transformation of the original B-1 clone, similar to the development of Richter's syndrome. An in vitro cell line was established from the aggressive lymphoma, which was stromal dependent and could rapidly metastasize when passaged into recipient animals. Analysis of adhesion molecules did not reveal any consistent characteristics that could account for the metastatic potential of the Richter's-like cells. In addition, the aggressive in vitro line had the identical heavy chain sequence as the slow growing NZB malignant B-1 clones. The in vitro and in vivo aggressive B-1 cells had very high levels of IL-10 message, and underwent more apoptosis in response to anti-IgM than did nonaggressive B-1 clones. Taking these characteristics together, we have composed a comprehensive animal model system for human CLL that includes both the aged NZB mice for the early stage and the recipients of the in vitro B-1 line for the late stage or Richter's syndrome. This model system can be used to study, not only the ontogeny and genetic linkage of CLL, but also the regulatory factors involved in transformation and growth both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046247

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  MicroRNAs in mouse models of lymphoid malignancies.

Authors:  Nicola Zanesi; Yuri Pekarsky; Francesco Trapasso; George Calin; Carlo M Croce
Journal:  J Nucleic Acids Investig       Date:  2010

2.  The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.

Authors:  Erica Salerno; Yao Yuan; Brian J Scaglione; Gerald Marti; Alexander Jankovic; Fermina Mazzella; Maria Fernanda Laurindo; Daryl Despres; Sivasubramanian Baskar; Christoph Rader; Elizabeth Raveche
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

3.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Authors:  Elizabeth S Raveche; Erica Salerno; Brian J Scaglione; Vijaya Manohar; Fatima Abbasi; Yi-Chu Lin; Torgny Fredrickson; Pablo Landgraf; Sumant Ramachandra; Konrad Huppi; Jorge R Toro; Vincent E Zenger; Robert A Metcalf; Gerald E Marti
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

Review 4.  Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.

Authors:  Brian J Scaglione; Erica Salerno; Murugabaskar Balan; Frederick Coffman; Pablo Landgraf; Fatima Abbasi; Sergei Kotenko; Gerald E Marti; Elizabeth S Raveche
Journal:  Br J Haematol       Date:  2007-10-17       Impact factor: 6.998

5.  An engineered selenocysteine defines a unique class of antibody derivatives.

Authors:  Thomas Hofer; Joshua D Thomas; Terrence R Burke; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

6.  Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Authors:  S Kasar; C Underbayev; Y Yuan; M Hanlon; S Aly; H Khan; V Chang; M Batish; T Gavrilova; F Badiane; H Degheidy; G Marti; E Raveche
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

7.  Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.

Authors:  Chingiz Underbayev; Siddha Kasar; William Ruezinsky; Heba Degheidy; Joel Solomon Schneider; Gerald Marti; Steven R Bauer; Diego Fraidenraich; Marilyn M Lightfoote; Vijay Parashar; Elizabeth Raveche; Mona Batish
Journal:  Oncotarget       Date:  2016-09-20

8.  Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL).

Authors:  Siddha Kasar; Chingiz Underbayev; Moinuddin Hassan; Ilko Ilev; Heba Degheidy; Steven Bauer; Gerald Marti; Carol Lutz; Elizabeth Raveche; Mona Batish
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.